By 2012 Pharmaceutical Growth inside Poland Should Hit Almost 6% in Nominal Terms According To Report 'Poland Pharmaceuticals and Healthcare Report Q3 2008'.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/9cd90f/poland_pharmaceuti) has announced the addition of the "Poland Pharmaceuticals and Healthcare Report Q3 2008" report to their offering. This report provides independent forecasts and competitive intelligence on Poland's pharmaceuticals and healthcare industry. Growth in Poland's drug market in local currency terms is set to slow down over the next few years but should return to strength by the end of the forecast period. The main deflationary de·fla·tion n. 1. The act of deflating or the condition of being deflated. 2. A persistent decrease in the level of consumer prices or a persistent increase in the purchasing power of money because of a reduction in available factors include the government stockpiling stock·pile n. A supply stored for future use, usually carefully accrued and maintained. tr.v. stock·piled, stock·pil·ing, stock·piles To accumulate and maintain a supply of for future use. the reimbursement Reimbursement Payment made to someone for out-of-pocket expenses has incurred. list with generics, at the expense of patented pharmaceuticals, and the possibility of even more stringent price restrictions. However, by 2012 growth should hit almost 6% in nominal terms, outpacing the rest of the economy, driven by rising GDP GDP (guanosine diphosphate): see guanine. and increased consumer spending Consumer demand or consumption is also known as personal consumption expenditure. It is the largest part of aggregate demand or effective demand at the macroeconomic level. power. In March 2008, the Ministry of Health has released a list of pharmaceutical and medical products eligible for full or partial reimbursement, along with the proposed reimbursement sums for each drug class. This declaration of reimbursement figures is a change from previous policy, in which the reimbursement levels were calculated in relation to the cheapest drug in a particular class. As expected, the new list has faced strong criticism from multinational drugmakers who believe that the measures are anti-competitive, and are fearful that the authorities are moving towards a system in which only one drug will be reimbursed in each therapeutic class. In terms of company activity, this quarter has been quiet, with Hungary's Richter still digesting Polish drug maker Polpharma after its multibillion move for the company at the end of 2007. BMI BMI body mass index. BMI abbr. body mass index Body mass index (BMI) A measurement that has replaced weight as the preferred determinant of obesity. is confident that the deal will close by the end of this quarter after Polish regulators recently approved the transaction. However, this has yet to spark a consolidation scramble amongst local manufacturers. Not that concentration is always a good thing. In fact, regulators are considering re-working legislation concerning drug distribution as they are concerned that the major players have too strong a position and are stifling free competition. Meanwhile, Poland has slipped two places to joint 11th in the Business Environment Rankings, due to improvements in competing markets. Poland has actually increased its score compared to the last quarter due to a strengthening of its economic structures, as perceived by our Country Risk team. However, corruption remains a problem as underlined by a recent scandal involving prescription fraud on the reimbursement list. Key Topics Covered: Executive Summary Poland - Market Summary Industry Forecast Scenario Competitive Landscape BMI Forecast Modelling Companies Mentioned: - Polfa Warszawa - GlaxoSmithKline - Eli Lilly Eli Lilly can refer to:
- Gedeon Richter - Krka - Lek Lek (lĕk), northern arm of the Rhine River, 40 mi (64 km) long, branching from the Neder Rijn (Lower Rhine), central Netherlands, and flowing W into the Nieuwe Maas (New Meuse) River. It is navigable for its entire length. (Novartis/Sandoz) - Pliva (Barr Pharmaceuticals Barr Pharmaceuticals, Inc., (NYSE: [http://www.nyse.com/about/listed/lcddata.html?ticker=BRL BRL]) is global specialty pharmaceutical company that operates in more than 30 countries worldwide and is engaged in the development, manufacture and marketing of generic and ) - Polpharma For more information visit http://www.researchandmarkets.com/research/9cd90f/poland_pharmaceuti |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion